June 10, 2024 11:16 AM EDT
R&D

Skye's stock sinks fol­low­ing eye dis­ease fail­ure as com­pa­ny shifts fo­cus to obe­si­ty

Katherine Lewin

News Reporter

Skye Bio­science is aban­don­ing its en­tire eye dis­ease pipeline fol­low­ing a Phase 2a tri­al fail­ure, and it’s piv­ot­ing to one of the hottest cat­e­gories in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times